Voyager Therapeutics Inc.

3.46
-0.07 (-1.98%)
At close: Apr 25, 2025, 3:59 PM
3.36
-2.75%
After-hours: Apr 25, 2025, 04:08 PM EDT

Voyager Therapeutics Statistics

Share Statistics

Voyager Therapeutics has 55.21M shares outstanding. The number of shares has increased by 1.5% in one year.

Shares Outstanding 55.21M
Shares Change (YoY) 1.5%
Shares Change (QoQ) 1.06%
Owned by Institutions (%) 59.65%
Shares Floating 44.89M
Failed to Deliver (FTD) Shares 137
FTD / Avg. Volume 0.04%

Short Selling Information

The latest short interest is 2.93M, so 5.32% of the outstanding shares have been sold short.

Short Interest 2.93M
Short % of Shares Out 5.32%
Short % of Float 6.33%
Short Ratio (days to cover) 9.15

Valuation Ratios

The PE ratio is -5.03 and the forward PE ratio is -2.13. Voyager Therapeutics's PEG ratio is 0.04.

PE Ratio -5.03
Forward PE -2.13
PS Ratio 4.09
Forward PS 2.9
PB Ratio 1.09
P/FCF Ratio -17.36
PEG Ratio 0.04
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Voyager Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 5.56, with a Debt / Equity ratio of 0.15.

Current Ratio 5.56
Quick Ratio 5.56
Debt / Equity 0.15
Debt / EBITDA -0.53
Debt / FCF -2.32
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $465.12K
Profits Per Employee $-377.92K
Employee Count 172
Asset Turnover 0.2
Inventory Turnover n/a

Taxes

Income Tax 665K
Effective Tax Rate -1.03%

Stock Price Statistics

The stock price has increased by -52.29% in the last 52 weeks. The beta is 1.02, so Voyager Therapeutics's price volatility has been higher than the market average.

Beta 1.02
52-Week Price Change -52.29%
50-Day Moving Average 3.75
200-Day Moving Average 5.87
Relative Strength Index (RSI) 52.72
Average Volume (20 Days) 375.37K

Income Statement

In the last 12 months, Voyager Therapeutics had revenue of 80M and earned -65M in profits. Earnings per share was -1.13.

Revenue 80M
Gross Profit 80M
Operating Income -83.29M
Net Income -65M
EBITDA -83.29M
EBIT -83.29M
Earnings Per Share (EPS) -1.13
Full Income Statement

Balance Sheet

The company has 71.37M in cash and 43.73M in debt, giving a net cash position of 27.64M.

Cash & Cash Equivalents 71.37M
Total Debt 43.73M
Net Cash 27.64M
Retained Earnings -326.18M
Total Assets 393.05M
Working Capital 227.02M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -15.31M and capital expenditures -3.52M, giving a free cash flow of -18.83M.

Operating Cash Flow -15.31M
Capital Expenditures -3.52M
Free Cash Flow -18.83M
FCF Per Share -0.33
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -104.11% and -81.25%.

Gross Margin 100%
Operating Margin -104.11%
Pretax Margin -80.42%
Profit Margin -81.25%
EBITDA Margin -104.11%
EBIT Margin -104.11%
FCF Margin -23.54%

Dividends & Yields

VYGR does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for VYGR is $12, which is 239% higher than the current price. The consensus rating is "Buy".

Price Target $12
Price Target Difference 239%
Analyst Consensus Buy
Analyst Count 8
Stock Forecasts

Scores

Altman Z-Score 0.23
Piotroski F-Score 3